OBJECTIVE： To provide reference for specified labeling of medication information on pregnant women in drug instructions of anti-diabetic drugs. METHODS： All of drug instructions of anti-diabetic drugs in DXY Drugs Information were collected， the medication information labeling on pregnant women was analyzed. RESULTS： Among 166 drug instructions， 147 （88.55％） had listed the item of “drug use for pregnant and lactating women” alone， and labeled with the drug information on pregnant women； 14 （8.43％） had listed the item too， but labeled with no or limited clinical data， and whether pregnant women could use or not was not suggested； 5 （3.01％） didn’t have the item. About without guidance of drug use， there were 3 （1.81％） drug instructions missed guidance， and 14 （8.43％） with no or limited clinical data. About with guidance of drug use， 49 （29.52％） were labeled with forbidden for pregnant women； 40 （24.1％） were labeled with can’t/not suitable/should not be used for pregnant women； 49 （29.52％） were labeled with cautious/not recommend/weighed the pros and cons/benefits greater than the risk/consulted a doctor for pregnant women； and 11 （6.63％） were labeled with being safe/being not restricted for pregnant women. In the 166 drug instructions， 26， which were from foreign pharmaceutical companies， had listed the item of “drug use for pregnant and lactating women” alone， as well as labeled the guidance of drug use for pregnant women. CONCLUSIONS： The labeling of domestic drug instructions shows inadequate drug information on pregnant women， non-uniform guidance statements， lag of update and other problems， which should be attached to great importance by drug supervision and management departments， as well as pharmaceutical production enterprises.